Denovo Bioinnovations targets surgeon ergonomics

Denovo Bioinnovations is making a specific pitch in surgical devices: not just that its suturing tools are novel, but that they are easier for surgeons to hold, learn and use in real operating-room conditions. The Pune-based company says it is building handheld wound-closure and laparoscopic suturing systems designed to reduce procedural complexity for surgeons in minimally invasive surgery. Its public materials center the ergonomic handle, workflow fit and disposable-cartridge setup alongside the underlying mechanics. That framing matters because Denovo is not presenting its products only as a robotics or precision story. The company says its platform technology is meant to make laparoscopic suturing “easy to learn, perform and master,” and its website describes an automated needle driver with an ergonomically designed handle and six degrees of freedom. ### Why is Denovo talking so much about ergonomics? Denovo’s own website says its innovations begin with “a surgeon’s challenge,” and that it designs instruments intended to reduce complexity for surgeons while improving efficiency and patient outcomes. (denovobioinnovations.com) The company describes traditional laparoscopic suturing as skill-intensive and time-consuming, and says its device combines automation with ergonomic design to support surgeons through the procedure. PitchBook’s company profile similarly describes Denovo as developing ergonomic laparoscopic instruments intended to improve dexterity, suturing control and surgeon comfort. That language aligns with the company’s broader message that usability at the hand-instrument level is part of the product itself, not a secondary feature. ### What exactly is the company building? Denovo says it specializes in advanced wound-closure systems, with an initial focus on automated laparoscopic suturing for minimally invasive surgeries. (denovobioinnovations.com) Its named products are SutureSure, which it has described as India’s first automated suturing system, and LapSure, an advanced laparoscopic suturing tool, both built on what it calls SmartStitch technology. The company’s website also highlights a proprietary needle, a patented needle-driving mechanism offering 360-degree needle control, and a single-use disposable cartridge intended to reduce setup time and maintain consistency and safety. (pitchbook.com) A published patent application tied to wound closure describes a suture cartridge containing a curved needle with thread and a needle-driving assembly for extracorporeal and intracorporeal suturing. (denovobioinnovations.com) ### Where does affordability enter the pitch? A January 8, 2025 funding announcement said Denovo had raised ₹1.96 crore in a round led by Campus Angels Network. In that release, the company said the money would go toward product development, clinical validation, regulatory approvals and commercialization. The same release said Denovo uses a “razor-razor blade” model that combines reusable devices with disposable cartridges. (denovobioinnovations.com) That structure is a standard way medtech companies try to balance upfront equipment cost with recurring consumables, and in Denovo’s case it supports the company’s broader argument that adoption depends on how a product fits hospital purchasing and surgical workflow. That reading is an inference from the disclosed business model and product design, not a separate company statement. (seedfund.venturecenter.co.in) ### Is there evidence that ergonomics can affect surgical adoption? A 2026 randomized experimental study published in *Hernia* found that a handheld suturing device called SutureTOOL improved ergonomic outcomes versus a traditional needle driver in aponeurotic closure testing. Denovo is not the subject of that study, but the paper shows that ergonomics in suturing devices is measurable and is being evaluated in the surgical literature, not treated only as a marketing claim. (seedfund.venturecenter.co.in) Denovo’s own materials make a similar case in product terms. The company says its mission is to equip surgeons with instruments that simplify complex procedures and make surgery easier, faster and more accessible. ### What comes next for Denovo? Denovo said in January 2025 that the new funding would help it complete pre-clinical and clinical studies, secure regulatory approvals and prepare its products for commercialization. (link.springer.com) The company also says it holds two granted patents and nine pending patents across India, the United States, Europe and other regions. Its website now presents the company as focused on advanced handheld surgical robotics for minimally invasive surgery, with SutureSure and LapSure as flagship offerings. (denovobioinnovations.com) The next concrete milestones are the ones Denovo itself named: validation studies, regulatory clearances and commercial rollout. (seedfund.venturecenter.co.in)